Pioneering the future of longevity care through the clinical advancement of exosome technology, Human Continuum has closed a $5.1M seed funding round. The startup is developing a standardized, cell-free biologic, enriched with regenerative signals, aimed at promoting systemic rejuvenation, reducing inflammation, and optimizing cellular health.
This capital infusion positions Human Continuum to further its work on its flagship product, aiming to become a cornerstone of the emerging longevity market.













